Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 2024 per tanggal 31 Maret 2024 (233 artikel)
Publikasi Scopus 2024 per tanggal 31 Maret 2024 (233 artikel)
Chairunnisa, Sheila (57539395900); Mustopa, Apon Zaenal (56781558900); Bela, Budiman (24723637900); Firdaus, Moh Egy Rahman (57827416000); Irawan, Shasmita (57218904860); Arifah, Rosyida Khusniatul (58286909200); Irawan, Herman (58650668500); Nurfatwa, Maritsa (57210969588); Umami, Rifqiyah Nur (55946476700); Ekawati, Nurlaili (57218911049); Hertati, Ai (57219869357); Hasan, Nurhasni (56600684900)
Expression and scale-up production of recombinant human papillomavirus type 52 L1 protein in methylotrophic yeast Hansenula polymorpha
2024
Journal of Genetic Engineering and Biotechnology
22
1
100342
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184803938&doi=10.1016%2fj.jgeb.2023.100342&partnerID=40&md5=3a2e0797d0ae426e695bdd52847dc388
Master's Programme in Biomedical Sciences, Faculty of Medicine Universitas Indonesia, Jakarta, 10430, Indonesia; Research Center for Genetic Engineering, National Research and Innovation Agency (BRIN), Bogor, 16911, Indonesia; Department of Microbiology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Faculty of Pharmacy, Universitas Hasanuddin, Jl. Perintis Kemerdekaan Km 10, Makassar, 90245, Indonesia
Background: Human papillomavirus (HPV) vaccination is one of the crucial national vaccination programs aimed at reducing the prevalence of the diseases associated with HPV infections, which continue to pose a global health concern. However, a significant disparity exists in the distribution of HPV vaccine, particularly in low-middle income countries where the cost of HPV vaccine becomes a major obstacle. Thus, it is essential to ensure the availability of an economically feasible HPV vaccine, necessitating immediate efforts to enhance the cost-effectiveness of vaccine production. This study aimed to develop an efficient production system for the recombinant HPV type 52 L1 protein as HPV vaccine material using methylotrophic yeast Hansenula polymorpha expression system. Results: This study presents an in-depth examination of the expression and scale-up production of HPV type 52 L1 protein using DASGIP® parallel bioreactor system. The pHIPX4 plasmid, which is regulated by the MOX promoter, generates stable clones that express the target protein. Cultivation employing the synthetic medium SYN6(10) with controlled parameters (e.g. temperature, pH, feeding strategy, and aeration) produces 0.15 µg/mL of HPV type 52 L1 protein, suggesting a possibility for scaling up to a higher production level. Conclusion: The scale-up production of HPV type 52 L1 protein using Hansenula polymorpha expression system described in this study provides an opportunity for an economical manufacturing platform for the development of the HPV vaccine. © 2024
National Research and Innovation Agency/Badan; Lembaga Pengelola Dana Pendidikan, LPDP, (B-1738/II.7.5/FR/11/2022)
This study was supported by National Research and Innovation Agency/Badan Riset dan Inovasi Nasional (BRIN) and Lembaga Pengelola Dana Pendidikan (LPDP) under scheme of Program Riset dan Inovasi untuk Indonesia Maju (RIIM) with the contract number: No. B-1738/II.7.5/FR/11/2022.
Elsevier B.V.
1687157X
Article
Q2
560
9245